Reorganization of HAS structure in France

The new Department of Evaluation and Access to Innovation will be responsible for the assessment of health technologies as well as public health. The strategic priorities of the Department are the following:

• Implementation of new systems for early access to health products and organization of their monitoring in real life;
• Setting up an integrated assessment of health products combining medico-technical and medico-economic components;
• Involvement in developing evaluation methods at the international level;
• Improvement of evaluation of vaccines and public health.

The DEAI includes four services (drug evaluation service, device evaluation service, evaluation service for procedures, public health and vaccine evaluation service) and two coordination units (coordination unit on real-life data, medico-economic coordination unit).

Because of global changes in health care due to the COVID-19 pandemic, the HAS aims to make more use of its expertise and intensify its presence within international bodies. The international mission specific to DEAI is to establish the agency's influence internationally (strengthen its presence and visibility, positioning in European projects, and building an international cooperation strategy).

The reorganization of HAS is part of all the reflections undertaken by the institution that demonstrates its ability to adapt to changes in health care.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).